Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Glycomimetics Inc (NQ: GLYC ) 0.1782 -0.0010 (-0.56%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Glycomimetics Inc < Previous 1 2 3 Next > GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan July 25, 2024 From GlycoMimetics, Inc. Via Business Wire GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) June 04, 2024 From GlycoMimetics, Inc. Via Business Wire GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024 May 29, 2024 From GlycoMimetics, Inc. Via Business Wire GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) May 06, 2024 From GlycoMimetics, Inc. Via Business Wire GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024 April 25, 2024 From GlycoMimetics, Inc. Via Business Wire GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023 March 27, 2024 From GlycoMimetics, Inc. Via Business Wire GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024 March 13, 2024 From GlycoMimetics, Inc. Via Business Wire GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference February 26, 2024 From GlycoMimetics, Inc. Via Business Wire GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) February 12, 2024 From GlycoMimetics, Inc. Via Business Wire GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687 January 04, 2024 From GlycoMimetics, Inc. Via Business Wire Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia January 03, 2024 From Apollomics Inc. Via GlobeNewswire GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia December 10, 2023 From GlycoMimetics, Inc. Via Business Wire GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference November 09, 2023 From GlycoMimetics, Inc. Via Business Wire GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023 November 03, 2023 From GlycoMimetics, Inc. Via Business Wire GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023 October 20, 2023 From GlycoMimetics, Inc. Via Business Wire GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687 September 06, 2023 From GlycoMimetics, Inc. Via Business Wire GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference September 05, 2023 From GlycoMimetics, Inc. Via Business Wire GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) August 17, 2023 From GlycoMimetics, Inc. Via Business Wire GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023 August 02, 2023 From GlycoMimetics, Inc. Via Business Wire GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023 July 19, 2023 From GlycoMimetics, Inc. Via Business Wire GlycoMimetics Announces Its Addition to the Russell Microcap® Index June 26, 2023 From GlycoMimetics, Inc. Via Business Wire GlycoMimetics Announces U.S. Food and Drug Administration Clears Addition of Time-based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia June 15, 2023 From GlycoMimetics, Inc. Via Business Wire GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Conference May 31, 2023 From GlycoMimetics, Inc. Via Business Wire GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023 May 03, 2023 From GlycoMimetics, Inc. Via Business Wire GlycoMimetics to Report First Quarter 2023 Financial Results on May 3, 2023 April 26, 2023 From GlycoMimetics, Inc. Via Business Wire GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022 March 29, 2023 From GlycoMimetics, Inc. Via Business Wire GlycoMimetics to Report Fourth Quarter and 2022 Full Year Financial Results on March 29, 2023 March 16, 2023 From GlycoMimetics, Inc. Via Business Wire GlycoMimetics to Participate in Upcoming Cowen 43rd Annual Health Care Conference March 01, 2023 From GlycoMimetics, Inc. Via Business Wire GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) February 16, 2023 From GlycoMimetics, Inc. Via Business Wire GlycoMimetics Announces Continuation of Phase 3 Study of E-selectin Antagonist Uproleselan in Relapsed/Refractory AML to Originally Planned Final Analysis Following Interim Analysis by Independent Data Monitoring Committee February 15, 2023 From GlycoMimetics, Inc. Via Business Wire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.